Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
Author: Benzinga Newsdesk | March 04, 2024 08:32am
Neurogene Inc. (NASDAQ:NGNE) ("Neurogene" or "the Company"), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the expansion of its ongoing Phase 1/2 gene therapy clinical trial for NGN-401 for female pediatric patients with Rett syndrome and updates to enable more rapid enrollment in the trial.
Posted In: NGNE